NO317987B1 - Nye aminopyrrolinforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem - Google Patents
Nye aminopyrrolinforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem Download PDFInfo
- Publication number
- NO317987B1 NO317987B1 NO20005797A NO20005797A NO317987B1 NO 317987 B1 NO317987 B1 NO 317987B1 NO 20005797 A NO20005797 A NO 20005797A NO 20005797 A NO20005797 A NO 20005797A NO 317987 B1 NO317987 B1 NO 317987B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- group
- compounds
- branched
- linear
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 30
- 238000000034 method Methods 0.000 title claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- NPLSMQWSKZXZPD-UHFFFAOYSA-N 2,3-dihydropyrrol-1-amine Chemical class NN1CCC=C1 NPLSMQWSKZXZPD-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- 125000000732 arylene group Chemical class 0.000 claims abstract description 11
- 125000003118 aryl group Chemical group 0.000 claims abstract description 8
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 7
- 125000005649 substituted arylene group Chemical group 0.000 claims description 6
- -1 amine hydrochloride Chemical class 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000004982 aromatic amines Chemical class 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 208000037849 arterial hypertension Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012022 methylating agents Substances 0.000 claims description 2
- YBMVUXMKXCIESU-UHFFFAOYSA-N n-(dicyclopropylmethyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound C1CC1C(C1CC1)NC1=NCCC1 YBMVUXMKXCIESU-UHFFFAOYSA-N 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- TYDIKMXNMGJKNH-UHFFFAOYSA-N n-(2-cyclopropylphenyl)-2-methyl-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CC1CCC(NC=2C(=CC=CC=2)C2CC2)=N1 TYDIKMXNMGJKNH-UHFFFAOYSA-N 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract description 3
- 229920006395 saturated elastomer Polymers 0.000 abstract description 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005549 heteroarylene group Chemical class 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004957 naphthylene group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000008018 melting Effects 0.000 description 20
- 238000002844 melting Methods 0.000 description 20
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000004872 arterial blood pressure Effects 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000001105 femoral artery Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001111317 Chondrodendron tomentosum Species 0.000 description 3
- 239000008709 Curare Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 3
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 3
- 239000012080 ambient air Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000003191 femoral vein Anatomy 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- JSKOLQWFMXYJAF-UHFFFAOYSA-N 2-cyclopropylaniline Chemical compound NC1=CC=CC=C1C1CC1 JSKOLQWFMXYJAF-UHFFFAOYSA-N 0.000 description 2
- UBXDNWVNEZBDBN-UHFFFAOYSA-N 4-cyclopropylaniline Chemical compound C1=CC(N)=CC=C1C1CC1 UBXDNWVNEZBDBN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- YVIVRJLWYJGJTJ-UHFFFAOYSA-N gamma-Valerolactam Chemical compound CC1CCC(=O)N1 YVIVRJLWYJGJTJ-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XRNLPUUQLOMTGY-UHFFFAOYSA-N (2-nitrocyclopropyl)benzene Chemical compound [O-][N+](=O)C1CC1C1=CC=CC=C1 XRNLPUUQLOMTGY-UHFFFAOYSA-N 0.000 description 1
- XJDSAMKMVWIDSN-OZZZDHQUSA-N (2s,3s)-n-(dicyclopropylmethyl)-2,3-dimethyl-3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.C[C@H]1[C@@H](C)CC(NC(C2CC2)C2CC2)=N1 XJDSAMKMVWIDSN-OZZZDHQUSA-N 0.000 description 1
- URLVRPKEOGBFHJ-RFZPGFLSSA-N (4r,5r)-4,5-dimethylpyrrolidin-2-one Chemical compound C[C@@H]1CC(=O)N[C@@H]1C URLVRPKEOGBFHJ-RFZPGFLSSA-N 0.000 description 1
- URLVRPKEOGBFHJ-UHNVWZDZSA-N (4r,5s)-4,5-dimethylpyrrolidin-2-one Chemical compound C[C@@H]1CC(=O)N[C@H]1C URLVRPKEOGBFHJ-UHNVWZDZSA-N 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- QWUFWJDOPFEBCC-WLHGVMLRSA-N (e)-but-2-enedioic acid;n-(3,4-dicyclopropylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound OC(=O)\C=C\C(O)=O.C1CC1C(C(=C1)C2CC2)=CC=C1NC1=NCCC1 QWUFWJDOPFEBCC-WLHGVMLRSA-N 0.000 description 1
- XJDSAMKMVWIDSN-UHFFFAOYSA-N (e)-dicyclopropylmethyl-(4,5-dimethylpyrrolidin-2-ylidene)azanium;chloride Chemical compound Cl.CC1C(C)CC(NC(C2CC2)C2CC2)=N1 XJDSAMKMVWIDSN-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- GDHGYIFNGNIROW-UHFFFAOYSA-N 1,2-dicyclopropylbenzene Chemical compound C1CC1C1=CC=CC=C1C1CC1 GDHGYIFNGNIROW-UHFFFAOYSA-N 0.000 description 1
- QRBMHYRZISIZNP-UHFFFAOYSA-N 1,3-dicyclopropylbenzene Chemical compound C1CC1C1=CC=CC(C2CC2)=C1 QRBMHYRZISIZNP-UHFFFAOYSA-N 0.000 description 1
- CEVMPTUTKPDFCP-UHFFFAOYSA-N 1,4-dicyclopropylbenzene Chemical compound C1CC1C1=CC=C(C2CC2)C=C1 CEVMPTUTKPDFCP-UHFFFAOYSA-N 0.000 description 1
- NWKFTTYCSJGVPB-UHFFFAOYSA-N 1-cyclopropyl-4-nitrobenzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1CC1 NWKFTTYCSJGVPB-UHFFFAOYSA-N 0.000 description 1
- AHFWKTKIRQCWCQ-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrol-5-amine Chemical group NC1=CCCN1 AHFWKTKIRQCWCQ-UHFFFAOYSA-N 0.000 description 1
- YLKSGSXUIWMBHJ-UHFFFAOYSA-N 2,4-dicyclopropylaniline Chemical compound NC1=CC=C(C2CC2)C=C1C1CC1 YLKSGSXUIWMBHJ-UHFFFAOYSA-N 0.000 description 1
- VIIXIPYJFXAWDI-UHFFFAOYSA-N 2,5-dicyclopropylaniline Chemical compound NC1=CC(C2CC2)=CC=C1C1CC1 VIIXIPYJFXAWDI-UHFFFAOYSA-N 0.000 description 1
- AXRUBPOKONMDEQ-UHFFFAOYSA-N 2-chloro-4-cyclopropylaniline Chemical compound C1=C(Cl)C(N)=CC=C1C1CC1 AXRUBPOKONMDEQ-UHFFFAOYSA-N 0.000 description 1
- IDXCCEOEOPTXEJ-UHFFFAOYSA-N 3,4-dicyclopropylaniline Chemical compound C1CC1C1=CC(N)=CC=C1C1CC1 IDXCCEOEOPTXEJ-UHFFFAOYSA-N 0.000 description 1
- JEBHLIYFPKISBI-UHFFFAOYSA-N 3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.NC1=NCCC1 JEBHLIYFPKISBI-UHFFFAOYSA-N 0.000 description 1
- BDEQMYVMSPSZHJ-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-(dicyclopropylmethyl)-3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C1CC(NC(C2CC2)C2CC2)=NC1 BDEQMYVMSPSZHJ-UHFFFAOYSA-N 0.000 description 1
- AOCWQPKHSMJWPL-UHFFFAOYSA-N 3-methylpyrrolidin-2-one Chemical compound CC1CCNC1=O AOCWQPKHSMJWPL-UHFFFAOYSA-N 0.000 description 1
- URLVRPKEOGBFHJ-UHFFFAOYSA-N 4,5-dimethylpyrrolidin-2-one Chemical compound CC1CC(=O)NC1C URLVRPKEOGBFHJ-UHFFFAOYSA-N 0.000 description 1
- KECQEMJTSJOCBD-UHFFFAOYSA-N 4-(hydroxymethyl)pyrrolidine-2-thione Chemical compound OCC1CNC(=S)C1 KECQEMJTSJOCBD-UHFFFAOYSA-N 0.000 description 1
- NJZDBGRSVWASIZ-UHFFFAOYSA-N 4-[(2-methylphenoxy)methyl]pyrrolidin-2-one Chemical compound CC1=CC=CC=C1OCC1CC(=O)NC1 NJZDBGRSVWASIZ-UHFFFAOYSA-N 0.000 description 1
- BBDPTNBIDTWCJX-UHFFFAOYSA-N 4-chloro-2-cyclopropylaniline Chemical compound NC1=CC=C(Cl)C=C1C1CC1 BBDPTNBIDTWCJX-UHFFFAOYSA-N 0.000 description 1
- YRKRGYRYEQYTOH-UHFFFAOYSA-N 4-methylpyrrolidin-2-one Chemical compound CC1CNC(=O)C1 YRKRGYRYEQYTOH-UHFFFAOYSA-N 0.000 description 1
- QMXPTUUFGSTIKK-UHFFFAOYSA-N 5-ethylpyrrolidin-2-one Chemical compound CCC1CCC(=O)N1 QMXPTUUFGSTIKK-UHFFFAOYSA-N 0.000 description 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XOMPUAADTYHYAG-UHFFFAOYSA-N N-(2-cyclopropylphenyl)-2-methyl-3,4-dihydro-2H-pyrrol-5-amine hydrochloride Chemical compound CC1CCC(=N1)NC2=CC=CC=C2C3CC3.Cl XOMPUAADTYHYAG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- VFSFCYAQBIPUSL-UHFFFAOYSA-N cyclopropylbenzene Chemical compound C1CC1C1=CC=CC=C1 VFSFCYAQBIPUSL-UHFFFAOYSA-N 0.000 description 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
- GDGUATCKWWKTLM-UHFFFAOYSA-N dicyclopropylmethanamine Chemical compound C1CC1C(N)C1CC1 GDGUATCKWWKTLM-UHFFFAOYSA-N 0.000 description 1
- BWWAFTOJAINBHN-UHFFFAOYSA-N dicyclopropylmethylazanium;chloride Chemical compound Cl.C1CC1C(N)C1CC1 BWWAFTOJAINBHN-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- IBHUHRPJPCKCQI-UHFFFAOYSA-N methyl 5-sulfanylidenepyrrolidine-3-carboxylate Chemical compound COC(=O)C1CNC(=S)C1 IBHUHRPJPCKCQI-UHFFFAOYSA-N 0.000 description 1
- ZQTRACOUSMJNEK-UHFFFAOYSA-N n-(2,4-dicyclopropylphenyl)-3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.C1CC1C(C=C1C2CC2)=CC=C1NC1=NCCC1 ZQTRACOUSMJNEK-UHFFFAOYSA-N 0.000 description 1
- QQLIADFZSYICHD-UHFFFAOYSA-N n-(2-chloro-4-cyclopropylphenyl)-3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.ClC1=CC(C2CC2)=CC=C1NC1=NCCC1 QQLIADFZSYICHD-UHFFFAOYSA-N 0.000 description 1
- BJXOCXDOBNCWLN-UHFFFAOYSA-N n-(2-cyclopropylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound C1CC1C1=CC=CC=C1NC1=NCCC1 BJXOCXDOBNCWLN-UHFFFAOYSA-N 0.000 description 1
- FAPDOZOXGDKRQY-UHFFFAOYSA-N n-(2-cyclopropylphenyl)-3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.C1CC1C1=CC=CC=C1NC1=NCCC1 FAPDOZOXGDKRQY-UHFFFAOYSA-N 0.000 description 1
- HNNKBLPYGNDYRX-UHFFFAOYSA-N n-(4-chloro-2-cyclopropylphenyl)-3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.C1CC1C1=CC(Cl)=CC=C1NC1=NCCC1 HNNKBLPYGNDYRX-UHFFFAOYSA-N 0.000 description 1
- ORBAWEGFCJLODT-UHFFFAOYSA-N n-(4-cyclopropylphenyl)-3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.C1CC1C(C=C1)=CC=C1NC1=NCCC1 ORBAWEGFCJLODT-UHFFFAOYSA-N 0.000 description 1
- RRLNUWRVTRDWIX-UHFFFAOYSA-N n-(4-cyclopropylphenyl)acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1CC1 RRLNUWRVTRDWIX-UHFFFAOYSA-N 0.000 description 1
- IAQBIXFIJISPGH-UHFFFAOYSA-N n-(dicyclopropylmethyl)-2-ethyl-3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.CCC1CCC(NC(C2CC2)C2CC2)=N1 IAQBIXFIJISPGH-UHFFFAOYSA-N 0.000 description 1
- NLBXASXQSWILFG-UHFFFAOYSA-N n-(dicyclopropylmethyl)-3,4-dihydro-2h-pyrrol-1-ium-5-amine;chloride Chemical compound [Cl-].C1CC1C(C1CC1)NC1=[NH+]CCC1 NLBXASXQSWILFG-UHFFFAOYSA-N 0.000 description 1
- ZTHCPGRIMLXOAH-UHFFFAOYSA-N n-(dicyclopropylmethyl)-3-[(2-methylphenoxy)methyl]-3,4-dihydro-2h-pyrrol-5-amine;hydrochloride Chemical compound Cl.CC1=CC=CC=C1OCC1CC(NC(C2CC2)C2CC2)=NC1 ZTHCPGRIMLXOAH-UHFFFAOYSA-N 0.000 description 1
- DRTGWFHXNUUWME-UHFFFAOYSA-N n-(dicyclopropylmethyl)-3-methyl-3,4-dihydro-2h-pyrrol-1-ium-5-amine;chloride Chemical compound [Cl-].C1C(C)C[NH+]=C1NC(C1CC1)C1CC1 DRTGWFHXNUUWME-UHFFFAOYSA-N 0.000 description 1
- DCQRJUFCMFXFQZ-UHFFFAOYSA-N n-(dicyclopropylmethyl)-4-methyl-3,4-dihydro-2h-pyrrol-1-ium-5-amine;chloride Chemical compound [Cl-].CC1CC[NH+]=C1NC(C1CC1)C1CC1 DCQRJUFCMFXFQZ-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9914434A FR2801051B1 (fr) | 1999-11-17 | 1999-11-17 | Nouveaux composes aminopyrroline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20005797D0 NO20005797D0 (no) | 2000-11-16 |
NO20005797L NO20005797L (no) | 2001-05-18 |
NO317987B1 true NO317987B1 (no) | 2005-01-17 |
Family
ID=9552203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20005797A NO317987B1 (no) | 1999-11-17 | 2000-11-16 | Nye aminopyrrolinforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem |
Country Status (23)
Country | Link |
---|---|
US (1) | US6300366B1 (zh) |
EP (1) | EP1101756B1 (zh) |
JP (1) | JP3274456B2 (zh) |
KR (1) | KR100453981B1 (zh) |
CN (1) | CN1158257C (zh) |
AT (1) | ATE234815T1 (zh) |
AU (1) | AU771745B2 (zh) |
BR (1) | BR0005442A (zh) |
CA (1) | CA2325781C (zh) |
DE (1) | DE60001706T2 (zh) |
DK (1) | DK1101756T3 (zh) |
EA (1) | EA004042B1 (zh) |
ES (1) | ES2194691T3 (zh) |
FR (1) | FR2801051B1 (zh) |
HK (1) | HK1036454A1 (zh) |
HU (1) | HUP0004543A3 (zh) |
MX (1) | MXPA00011239A (zh) |
NO (1) | NO317987B1 (zh) |
NZ (1) | NZ508228A (zh) |
PL (1) | PL343920A1 (zh) |
PT (1) | PT1101756E (zh) |
SI (1) | SI1101756T1 (zh) |
ZA (1) | ZA200006731B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003257418A1 (en) | 2002-06-19 | 2004-01-06 | Solvay Pharmaceuticals Gmbh | Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins |
GB0521083D0 (en) * | 2005-10-17 | 2005-11-23 | Novartis Ag | Organic compounds |
NZ717739A (en) | 2013-08-09 | 2023-12-22 | Ardelyx Inc | Compounds and methods for inhibiting phosphate transport |
GB201318886D0 (en) * | 2013-10-25 | 2013-12-11 | Givaudan Sa | Improvements i or relating to organic compounds |
CN114716359B (zh) * | 2022-04-28 | 2023-01-17 | 广东医科大学 | 一种氢化吲哚亚胺非对映异构体的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2029297A1 (de) * | 1970-06-13 | 1971-12-30 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Neue Aminophenyl-cycloamidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US3887569A (en) * | 1970-10-30 | 1975-06-03 | Mcneilab Inc | 2-Imino-piperidines |
NL7412695A (nl) * | 1974-09-26 | 1976-03-30 | Stamicarbon | De bereiding van een 2-amino-pyrrolinederivaat. |
US4579951A (en) * | 1984-03-19 | 1986-04-01 | G. D. Searle & Co. | Substituted (azacycloalk-2-yl)iminophenols and esters thereof |
DE4425070A1 (de) * | 1994-07-15 | 1996-01-18 | Degussa | Verfahren zur Herstellung optisch aktiver l-substituierter 2-(Aminomethyl)pyrrolidine |
-
1999
- 1999-11-17 FR FR9914434A patent/FR2801051B1/fr not_active Expired - Fee Related
-
2000
- 2000-11-09 SI SI200030067T patent/SI1101756T1/xx unknown
- 2000-11-09 AT AT00403106T patent/ATE234815T1/de not_active IP Right Cessation
- 2000-11-09 DE DE60001706T patent/DE60001706T2/de not_active Expired - Fee Related
- 2000-11-09 ES ES00403106T patent/ES2194691T3/es not_active Expired - Lifetime
- 2000-11-09 DK DK00403106T patent/DK1101756T3/da active
- 2000-11-09 PT PT00403106T patent/PT1101756E/pt unknown
- 2000-11-09 EP EP00403106A patent/EP1101756B1/fr not_active Expired - Lifetime
- 2000-11-14 JP JP2000346838A patent/JP3274456B2/ja not_active Expired - Fee Related
- 2000-11-15 MX MXPA00011239A patent/MXPA00011239A/es active IP Right Grant
- 2000-11-16 NZ NZ508228A patent/NZ508228A/xx unknown
- 2000-11-16 US US09/714,090 patent/US6300366B1/en not_active Expired - Fee Related
- 2000-11-16 EA EA200001077A patent/EA004042B1/ru not_active IP Right Cessation
- 2000-11-16 PL PL00343920A patent/PL343920A1/xx not_active Application Discontinuation
- 2000-11-16 HU HU0004543A patent/HUP0004543A3/hu unknown
- 2000-11-16 NO NO20005797A patent/NO317987B1/no unknown
- 2000-11-17 AU AU71680/00A patent/AU771745B2/en not_active Ceased
- 2000-11-17 ZA ZA200006731A patent/ZA200006731B/xx unknown
- 2000-11-17 CN CNB001285394A patent/CN1158257C/zh not_active Expired - Fee Related
- 2000-11-17 BR BR0005442-9A patent/BR0005442A/pt not_active IP Right Cessation
- 2000-11-17 CA CA002325781A patent/CA2325781C/fr not_active Expired - Fee Related
- 2000-11-17 KR KR10-2000-0068434A patent/KR100453981B1/ko not_active IP Right Cessation
-
2001
- 2001-10-24 HK HK01107419A patent/HK1036454A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0690843B1 (en) | Formyl- or cyano- substituted indole derivatives having dopaminergic activity | |
KR100885308B1 (ko) | 5-ht6 및/또는 5-ht7 세로토닌 수용체의리간드로서 사용되는 5-할로-트립타민 유도체 | |
HUT63624A (en) | Process for producing benzimidazole derivatives and pharmaceutical compositions comprising such compounds | |
DK164557B (da) | Derivater af cis,endo-2-azabicyclo-oe5.3.0aa-decan-3-carboxylsyre samt laegemiddel indeholdende dem | |
NO840486L (no) | Benzazocinon og benzazoninonderivater | |
JPH04334366A (ja) | インドール誘導体 | |
EP2161266A1 (en) | Benzofuran derivatives as orexin receptor antagonists | |
KR0128288B1 (ko) | 나프틸옥사졸리돈 유도체 | |
DK157995B (da) | Analogifremgangsmaade til fremstilling af indolderivater | |
CZ212594A3 (en) | Indole derivatives, process of their preparation, intermediates of such process, pharmaceutical compositions containing said derivatives and the use of the derivatives | |
WO1996016965A1 (fr) | Derives d'acrylamide et leur procede de production | |
NO317987B1 (no) | Nye aminopyrrolinforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
KR20010041341A (ko) | 벤질피페라지닐 및 벤질피페리디닐 에탄온 유도체, 이의제조 방법 및 도파민 d4 수용체 길항제로서의 이의 용도 | |
JPH05331135A (ja) | 新規なナフタミド誘導体と、その合成方法と、その治療分野への応用 | |
EA005160B1 (ru) | НОВЫЕ СОЕДИНЕНИЯ ОКТАГИДРО-2H-ПИРИДО[1,2-α]ПИРАЗИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ИХ СОДЕРЖАЩИЕ | |
JP3886829B2 (ja) | 新規インデノインドロン化合物、それらの調製方法およびそれらを含む医薬組成物 | |
CZ289080B6 (cs) | N-Substituovaný azabicykloheptanový derivát, způsob jeho výroby a pouľití | |
MXPA02002601A (es) | Compuestos nuevos de isoindoloindolona, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
DK165878B (da) | 3-substituerede-5-aminoalkyl-beta-carbolinderivater og fremgangsmaade til deres fremstilling | |
EA003300B1 (ru) | Новые замещенные димерные соединения, способ их получения и содержащая их фармацевтическая композиция | |
EP3189061A1 (fr) | Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques comme inhibiteurs de la ftl3 et jak | |
EP0767787B1 (en) | (3,4-dioxocyclobuten-1-yl)chromene, indene, and dihydronaphthalenone derivatives as smooth muscle relaxants | |
Liang et al. | Synthesis and Biological Activity of Some 1, 3‐Dihydro‐2H‐3‐benzazepin‐2‐ones with a Piperazine Moiety as Bradycardic Agents | |
JP3709203B2 (ja) | 5−ht1aレセプターに対して親和性をもつ三環式化合物 | |
GB2266716A (en) | Inhibitors of HIV reverse transcriptase |